The day before the Congressional hearing on the rising price and absence of competition for the EpiPen, West Virginia Attorney General Patrick Morrisey confirmed that he had issued a subpoena to Mylan.
The maker of EpiPen was issued a subpoena in August seeking documents and other information related to EpiPen, but the company failed to meet the September 7 deadline.
The state believes that EpiPen has been short-changing the West Virginia Department of Health and Human Services Bureau for Medical Services by paying smaller rebates than it should have, which may constitute Medicaid fraud under state law.
Morrisey claims that Mylan currently controls up to 90% of the US market for epinephrine auto-injectors, which has allowed it to increase prices from around $100 for a two-pack back in 2009 to more than $600 for the same two-pack today.
Full Content: The Consumerist
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
US Judge OKs $110 Million Settlements in Antitrust Case Against Major Real Estate Brokerages
Oct 31, 2024 by
CPI
50 States and Territories Reach $49.1 Million Settlement in Generic Drug Price-Fixing Case
Oct 31, 2024 by
CPI
OpenAI Enhances ChatGPT with New Search Feature, Challenging Google’s Dominance
Oct 31, 2024 by
CPI
First Circuit Hears Arguments on Whether Federal Baseball Antitrust Exemption Shields Puerto Rican League from Legal Claims
Oct 31, 2024 by
CPI
Federal Appeals Court Expresses Doubts Over FCC’s Authority in Net Neutrality Revival
Oct 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI